Medicinova, Inc. · NASDAQ:MNOV
Medicinova — Investor Presentation (September 2010)
14 slides from Medicinova's investor presentation, Sep 14, 2010
Slide 1: Accelerating the global development and commercialization of innovative pharmaceuticals
Accelerating the global development and commercialization of innovative pharmaceuticals Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements inc
Slide 3: Corporate Overview: MediciNova, Inc.
MediciNova Overview: • Founded in September 2000 • Headquartered in San Diego, CA • Additional office in Tokyo, Japan • Dual-listing on NasdaqGM as MNOV and Osaka Securities Exchange as 4875 • $71.7 million Market Cap (NasdaqGM) as of 8/2/2010 Development Company Focused on Differentiated Product Ca
Slide 4: MN-221 for Exacerbations of Acute Asthma and COPD
Definition: • Long-lasting and severe episodes that are not responsive to initial bronchodilator or corticosteroid therapies Market Opportunity*: • ~500,000 annual hospitalizations in the US for asthma • Average length of stay for asthma hospitalization is 3.2 days • Average cost for asthma hospital
Slide 5: Acute Asthma Treatment Flow in Emergency Departments in the U.S.
525,000 Acute Asthma Treatment Flow in Acute Asthma Treatment Flow in Emergency Departments in the U.S. Emergency Departments in the U.S. 1,900,000 1,900,000 Positive Response ~51% Continue therapy until patient is discharged Non- Responders ~49% Continue therapy for several hours Patient improves a
Slide 6: MN-221: A New Approach to Treating Exacerbations of Acute Asthma & COPD
1. Improved Efficacy • Route of Administration (IV v. Inhalation) 2. Improved Safety • Higher selectivity for 2 receptor than 1 • 42.4 fold 2 selectivity (IC 50 - 1 / IC 50 - 2 ) • Partial agonist for 1 receptor 3. Reduced Health Care Expenses MN-221: A novel, highly selective - adrenergic receptor
Slide 7: MN-221 Clinical Trials
MN-221 Clinical Trials MN-221 Clinical Trials Completed Completed Ongoing Ongoing Study Study CL-004 CL-005 CL-006 CL-010 CL-007 Indication Indication Mild-to-moderate Asthmatics Moderate-to- Severe Asthmatics Acute Exacerbations of Asthma Moderate-to- Severe COPD patients Acute Exacerbations of Ast
Slide 8: MN-221-CL-006: Mean Change in FEV and Differences in Hospitalization Rate
MN-221-CL-006 MN-221-CL-006 Mean Change in FEV Mean Change in FEV and and Differences in Hospitalization Rate Differences in Hospitalization Rate Mean change in FEV from baseline was 5.27% higher in the MN-221 dose groups versus the placebo group MN-221 reduced the hospitalization rate by 45%
Slide 9: MN-221-CL-007: Study Design
• Randomized, placebo-controlled, double-blind, multi-center Phase II clinical trial • Up to patients with severe, acute exacerbations of asthma (FEV 50% predicted) at multiple Emergency Department sites in the United States • Dose Groups (up to100 patients/group): • 1,200 µg MN-221 over hour (600 µ
Slide 10: MN-166 (Ibudilast) for the Treatment of MS, Neuropathic Pain and Addiction
MN-166 • Oral administration • Safe and well-tolerated (approved in Japan/Korea with over 3.2 million patient exposures) • Mechanism(s) of Action primarily non-selective PDE inhibition, Attenuation of Glial Cell Activation and Inhibition of Microphage Migration Inhibitor Factor (MIF) Clinical Safety
Slide 11: MN-166 for Opioid Withdrawal: Phase Ib/IIa Ongoing Clinical Trial
Trial Design/Endpoints Study Design: • Study Objective: Assess MN-166 safety/tolerability/PK and preliminary efficacy for opiate withdrawal in heroin-dependent subjects • Ongoing clinical trial run jointly by the New York State Psychiatric Institute and Columbia University in NYC (Investigator IND s
Slide 12: Commercially-Attractive Diversified Portfolio
COPD Asthma MS Pain/Addiction Commercially-Attractive Commercially-Attractive Diversified Portfolio Diversified Portfolio COPD Asthma MS Pain/Addiction
Slide 13: MediciNova
MEDICINOVA
Slide 14: Upcoming Near-Term Business Milestones
Upcoming Near-Term Business Milestones: 1. Secure a global partnership for MN-166 2. Secure a strategic partnership for MN-221 Upcoming Clinical Milestones: 1. MN-221-CL-007 Phase II Study for Acute Exacerbations of Asthma • Anticipated completion 1Q, 2011* 2. MN-166 Study for Opioid Withdrawal • An